E. Ohman J or Asset Management AB Grows Position in Laboratory Co. of America Holdings (NYSE:LH)

E. Ohman J or Asset Management AB grew its stake in shares of Laboratory Co. of America Holdings (NYSE:LH) by 22.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,400 shares of the medical research company’s stock after purchasing an additional 800 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Laboratory Co. of America were worth $1,009,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Private Trust Co. NA raised its holdings in shares of Laboratory Co. of America by 3.2% during the third quarter. Private Trust Co. NA now owns 1,342 shares of the medical research company’s stock valued at $300,000 after acquiring an additional 41 shares in the last quarter. Empirical Finance LLC raised its holdings in shares of Laboratory Co. of America by 1.7% during the third quarter. Empirical Finance LLC now owns 3,055 shares of the medical research company’s stock valued at $683,000 after acquiring an additional 50 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Laboratory Co. of America by 16.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 354 shares of the medical research company’s stock valued at $81,000 after acquiring an additional 50 shares in the last quarter. Concord Wealth Partners raised its holdings in shares of Laboratory Co. of America by 43.3% during the third quarter. Concord Wealth Partners now owns 172 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 52 shares in the last quarter. Finally, Rehmann Capital Advisory Group raised its holdings in shares of Laboratory Co. of America by 1.9% during the third quarter. Rehmann Capital Advisory Group now owns 2,844 shares of the medical research company’s stock valued at $637,000 after acquiring an additional 53 shares in the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on LH shares. Barclays upped their target price on Laboratory Co. of America from $249.00 to $271.00 and gave the company an “equal weight” rating in a report on Monday. UBS Group decreased their price objective on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. StockNews.com downgraded Laboratory Co. of America from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Bank of America increased their price objective on Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Finally, Evercore ISI upgraded Laboratory Co. of America from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $260.00 to $265.00 in a report on Tuesday, January 7th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $263.46.

Laboratory Co. of America Price Performance

Shares of NYSE:LH opened at $250.01 on Thursday. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $258.59. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The business has a fifty day moving average price of $236.30 and a 200-day moving average price of $229.20. The company has a market capitalization of $20.91 billion, a PE ratio of 48.36, a PEG ratio of 1.86 and a beta of 1.07.

Laboratory Co. of America Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Thursday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.15%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 55.71%.

Insider Activity at Laboratory Co. of America

In other Laboratory Co. of America news, CEO Adam H. Schechter sold 6,189 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $243.47, for a total value of $1,506,835.83. Following the transaction, the chief executive officer now directly owns 87,441 shares of the company’s stock, valued at approximately $21,289,260.27. This trade represents a 6.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Glenn A. Eisenberg sold 11,711 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $240.43, for a total value of $2,815,675.73. Following the completion of the transaction, the executive vice president now directly owns 31,289 shares in the company, valued at $7,522,814.27. The trade was a 27.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,572 shares of company stock valued at $5,915,209 over the last ninety days. Insiders own 0.85% of the company’s stock.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.